A biomarker is any biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. Specifically, a cancer biomarker can be a molecule secreted by tumor cells or by other cells in response to cancer and presence of these molecules can help detect cancer early and guide treatment decisions. Some key roles of cancer biomarkers include aiding early detection, assessing risk, monitoring response to treatment, and detecting recurrence. With advancements in medical technology, research on cancer biomarkers is helping revolutionize cancer management.
Types
These are broadly classified into three categories based on their function and source:
Genetic Biomarkers
Alterations in DNA and genes can serve as biomarkers. Mutations, deletions or overexpressions of certain genes in cancer cells compared to normal cells provide targets that can be measured as biomarkers. For example, mutations in the BRCA1/BRCA2 genes assessed through genetic testing help identify higher risk of breast and ovarian cancers.
Protein Biomarkers
Abnormal levels of proteins expressed by cancer cells or the body’s response to cancer make excellent Cancer Biomarkers. For example, prostate specific antigen or PSA is routinely used as a biomarker for prostate cancer screening and monitoring.
Imaging Biomarkers
Advanced imaging techniques like CT scans, MRIs, and PET scans detect physical changes in organs, tissues or tumors which act as imaging biomarkers. For example, a growing tumor seen on successive scans can serve as a biomarker to measure response to treatment.
Importance and Applications of Cancer Biomarkers
Early Detection: Some biomarkers like PSA, CA125 for ovarian cancer and CEAB for colorectal cancer allow detection of cancer even before clinical symptoms appear, improving chances of successful treatment.
Diagnosis: Measuring biomarkers aids pathologists in confirming tumor type and Primary site of cancer when diagnosing cancers with unclear origins like those detected via screening.
Prognosis: Certain biomarkers indicate aggressive subtypes with poorer prognosis allowing treatment plans tailored accordingly. For example, HER2 status in breast cancer.
Predicting Response: Biomarkers like hormone receptor status in breast cancer or KRAS mutation status in colorectal cancer predict if a patient will likely respond to targeted therapies. This guides personalized treatment decisions.
Monitoring Treatment: Serial scans of tumor biomarkers during and after treatment help assess treatment effectiveness and detect early recurrence. For example, declining PSA levels after prostate cancer treatment.
Developing New Drugs: Understanding disease mechanisms helps identify novel targets for drug development. Many modern targeted drugs were developed based on insights gained from biomarkers.
Personalized Medicine: Integration of multiple biomarker parameters along with other factors provide a multidimensional view of the disease in an individual allowing truly personalized management approaches.
Challenges and Future of Cancer Biomarkers
Despite many advances, widespread clinical use of cancer biomarkers still faces hurdles. Additional research is needed to discover highly reliable biomarkers for various cancer types and stages. Standardization of biomarker tests remains a challenge affecting reproducibility and clinical validation of research findings. Cost and complexity of some biomarker tests pose accessibility issues in developing nations and even some developed countries. Machine learning and artificial intelligence may help discover subtle patterns in biomarker data accelerating discovery of novel biomarkers. With focus on precision oncology, biomarker-driven management of cancer looks set to transform patient outcomes in the coming decades.
Get more insights on Cancer Biomarkers
